{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Dans les cas de m\u00e9lanome, la biopsie des ganglions sentinelles (BGS) est d\u00e9terminante pour le pronostic et l\u2019orientation des traitements et des strat\u00e9gies de surveillance. Malgr\u00e9 des lignes directrices largement publi\u00e9es pour la BGS, son utilisation est variable. Nous avons voulu d\u00e9terminer la fr\u00e9quence des BGS et les facteurs propices \u00e0 son utilisation chez les patients atteints de m\u00e9lanome dont les ganglions sont cliniquement n\u00e9gatifs en Colombie-Britannique.",
        "Une revue r\u00e9trospective des cas de m\u00e9lanome avec ganglions cliniquement n\u00e9gatifs a \u00e9t\u00e9 effectu\u00e9e entre janvier 2015 et d\u00e9cembre 2017. Les patients inclus pr\u00e9sentaient un indice de Breslow sup\u00e9rieur \u00e0 0,75 mm ou inf\u00e9rieur ou \u00e9gal \u00e0 0,75 mm avec ulc\u00e9ration, ou un taux mitotique sup\u00e9rieur ou \u00e9gal \u00e0 1/mm<sup>2</sup>. La BGS \u00e9tait jug\u00e9e indiqu\u00e9e pour les stades cliniques IB \u00e0 IIC (septi\u00e8me \u00e9dition de l\u2019<i>AJCC Cancer Staging Manual</i> de l\u2019American Joint Committee on Cancer).",
        "En tout, 759 patients ont \u00e9t\u00e9 inclus. Une BGS a \u00e9t\u00e9 effectu\u00e9e chez 54,8 % (363/662) d\u2019entre eux lorsqu\u2019elle \u00e9tait indiqu\u00e9e. La BGS \u00e9tait plus susceptible d\u2019\u00eatre effectu\u00e9e en pr\u00e9sence de tumeurs ayant un indice de Breslow sup\u00e9rieur \u00e0 1,0 mm ou un taux mitotique sup\u00e9rieur ou \u00e9gal \u00e0 1/mm<sup>2</sup>. La BGS \u00e9tait moins susceptible d\u2019\u00eatre effectu\u00e9e chez les patients de plus de 75 ans qui pr\u00e9sentaient une tumeur n\u2019affectant pas les membres. Le respect des lignes directrices relatives \u00e0 la BGS a permis de r\u00e9duire les r\u00e9cidives \u00e0 distance, mais n\u2019a pas affect\u00e9 significativement les r\u00e9currences r\u00e9gionales et n\u2019a pas eu d\u2019impact significatif sur la survie globale chez les patients de 75 ans et moins.",
        "La BGS est sous-utilis\u00e9e en Colombie-Britannique. Ces conclusions sont inqui\u00e9tantes et tr\u00e8s importantes compte tenu de l\u2019\u00e9volution rapide des traitements adjuvants syst\u00e9miques pour les patients \u00e0 haut risque et de la proportion croissante de patients qui y seraient candidats selon la huiti\u00e8me \u00e9dition de l\u2019<i>AJCC Cancer Staging Manual</i> et les lignes directrices actuelles. Il faut d\u00e9ployer des efforts pour accro\u00eetre l\u2019utilisation de la BGS chez les patients qui y sont candidats."
      ],
      "CopyrightInformation": "\u00a9 2022 CMA Impact Inc. or its licensors."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35701006",
  "DateCompleted": {
    "Year": "2022",
    "Month": "06",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "12",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "06",
        "Day": "14"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1503/cjs.019320"
    ],
    "Journal": {
      "ISSN": "1488-2310",
      "JournalIssue": {
        "Volume": "65",
        "Issue": "3",
        "PubDate": {
          "Year": "2022",
          "Season": "May-Jun"
        }
      },
      "Title": "Canadian journal of surgery. Journal canadien de chirurgie",
      "ISOAbbreviation": "Can J Surg"
    },
    "ArticleTitle": "Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma.",
    "Pagination": {
      "StartPage": "E394",
      "EndPage": "E403",
      "MedlinePgn": "E394-E403"
    },
    "Abstract": {
      "AbstractText": [
        "Sentinel lymph node biopsy (SLNB) for melanoma plays a central role in determining prognosis and guiding treatment and surveillance strategies. Despite widely published guidelines for SLNB, variation exists in its use. We aimed to determine the frequency of and predictive factors for SLNB in patients with clinically node-negative melanoma in British Columbia.",
        "A retrospective review was performed of patients with clinically node-negative melanoma diagnosed between January 2015 and December 2017. Patients included had a Breslow depth greater than 0.75 mm or a Breslow depth less than or equal to 0.75 mm with ulceration, or a mitotic rate greater than or equal to 1/mm<sup>2</sup>. SLNB was considered to be indicated for clinical stages IB to IIC (American Joint Committee on Cancer's <i>AJCC Cancer Staging Manual</i>, seventh edition).",
        "A total of 759 patients were included. SLNB was performed in 54.8% (363/662) of patients when indicated. SLNB was more likely to be performed for tumours with a Breslow depth greater than 1.0 mm or a mitotic rate greater than or equal to 1/mm<sup>2</sup>. SLNB was less likely to be performed in patients older than 75 years and with a nonextremity tumour location. Compliance with SLNB guidelines decreased distant recurrence but did not significantly affect regional recurrence, nor did it have a significant impact on overall survival among patients aged 75 years and younger.",
        "SLNB is being underutilized in British Columbia. These results are concerning and highly relevant given the rapidly evolving field of adjuvant systemic therapy for high-risk patients and the increased proportion of patients who should be considered for SLNB on the basis of the eighth edition of the <i>AJCC Cancer Staging Manual</i> and current guidelines. Efforts should be made to increase the use of SLNB in appropriate patients."
      ],
      "CopyrightInformation": "\u00a9 2022 CMA Impact Inc. or its licensors."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart) sita.ollek@interiorhealth.ca."
          }
        ],
        "LastName": "Ollek",
        "ForeName": "Sita",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Minkova",
        "ForeName": "Stephanie",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Taqi",
        "ForeName": "Kadhim",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Chen",
        "ForeName": "Leo",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Martinka",
        "ForeName": "Magdalena",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Davis",
        "ForeName": "Noelle",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Hamilton",
        "ForeName": "Trevor",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart)."
          }
        ],
        "LastName": "Stuart",
        "ForeName": "Heather",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Canada",
    "MedlineTA": "Can J Surg",
    "NlmUniqueID": "0372715",
    "ISSNLinking": "0008-428X"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pathology",
        "surgery"
      ],
      "DescriptorName": "Melanoma"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Staging"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sentinel Lymph Node Biopsy"
    },
    {
      "QualifierName": [
        "pathology",
        "surgery"
      ],
      "DescriptorName": "Skin Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Melanoma, Cutaneous Malignant"
    }
  ],
  "CoiStatement": "Competing interests: None declared."
}